LAMISIL Drug Patent Profile

Which patents cover Lamisil, and when can generic versions of Lamisil launch?

Lamisil is a drug marketed by Karo Hlthcare and Novartis and is included in eight NDAs.

The generic ingredient in LAMISIL is terbinafine. There are twenty-seven drug master file entries for this compound. Additional details are available on the terbinafine profile page.

Summary for LAMISIL

US Patents:	0
Applicants:	2
NDAs:	8

US Patents and Regulatory Information for LAMISIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Karo Hlthcare	LAMISIL	terbinafine hydrochloride	CREAM;TOPICAL	020980-001	Mar 9, 1999		OTC	Yes	Yes
Novartis	LAMISIL	terbinafine hydrochloride	TABLET;ORAL	020539-001	May 10, 1996		DISCN	Yes	No
Novartis	LAMISIL	terbinafine hydrochloride	GRANULE;ORAL	022071-001	Sep 28, 2007		DISCN	Yes	No
Karo Hlthcare	LAMISIL AT	terbinafine	GEL;TOPICAL	021958-001	Jul 24, 2006		OTC	Yes	Yes

International Patents for LAMISIL

See the table below for patents covering LAMISIL around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	60877	PROPENYLAMINES,THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
Finland	65774
Hungary	T62466
Ireland	50878	PROPENYLAMINES,PROCESSES FOR THEIR PRODUCTION,PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS PHARMACEUTICALS

Supplementary Protection Certificates for LAMISIL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0024587	93C0136	Belgium		PRODUCT NAME: TERBINAFINE (250 MG) SOUS FORME DE CHLORHYDRATE (281,25 MG); NAT. REG.: 616 S 201 F3 19911031; FIRST REG.: GB PL 0101/0304 19901003
0024587	SPC/GB93/096	United Kingdom		SPC/GB93/096, EXPIRES: 20050805

Investment Scenario, Market Dynamics, and Financial Trajectory of LAMISIL (Terbinafine)

Last updated: February 3, 2026

Summary

LAMISIL (generic name: terbinafine) is an antifungal medication primarily used to treat dermatophyte infections such as athlete's foot, jock itch, and ringworm, as well as onychomycosis (fungal nail infections). The drug's strong market position, patent expirations, and increasing global prevalence of fungal infections shape its investment landscape. This analysis covers LAMISIL's market performance, competitive environment, regulatory factors, and projected financial trajectory, supported by recent data and strategic trends.

---

1. Market Overview and Dynamics

Global Market Size and Growth Trends

Year	Market Size (USD billion)	CAGR (2019-2025)	Key Drivers
2019	$0.8	4.8%	Rising fungal infections, aging populations, increased diagnostics
2020	$0.84		Pandemic-induced healthcare access shifts
2021	$0.89		Growth in dermatophyte infections, increased awareness
2022	$0.94		Expansion into emerging markets
2023	$1.00	5.0%	Launch of new formulations, competitive dynamics

Market Segmentation

Segment	Market Share (%)	Description
Onychomycosis	55%	Largest segment due to high prevalence in aging populations
Tinea infections	35%	Includes athlete’s foot, ringworm
Other fungal infections	10%	Less common, includes candidiasis

Regional Market Distribution

Region	Market Share (%)	Key Characteristics
North America	40%	Market maturity, high healthcare access
Europe	25%	Strong healthcare infrastructure, aging demographics
Asia-Pacific	20%	Fastest growth, rising fungal infection incidence
Latin America & Africa	15%	Emerging markets, expanding healthcare infrastructure

---

2. Competitive Landscape

Major Players

Company	Market Share (%)	Key Products	Notable Developments
Novartis (Nizoral, etc.)	35%	LAMISIL, other antifungals	Patent expiry, biosimilar emergence
GlaxoSmithKline (Lamisil AT)	25%	LAMISIL (brand & generics)	Continued marketing, potential biosimilar threats
Dr. Reddy’s Laboratories	10%	Generic terbinafine	Expanding in emerging markets
Others	30%	Various local generic brands	Increased price competition

Patent and Patent Expiry Impact

• The original LAMISIL patent expired in the US in 2014, with subsequent generics entering the market, diminishing overall revenue.
• Patents in some regional markets continued until 2020.
• The consequences include declining margins but increased volume sales through generics.

Emerging Competition and Biosimilars

Trend	Impact
Biosimilars & Generics	Lower price points, increased competition
Novel antifungal agents	Potential pipeline rivals reducing LAMISIL’s market share
OTC availability & self-medication	Flattens prescription-based revenue streams

---

3. Regulatory Environment and Patent Landscape

Regulatory Status

Region	Regulatory Agency	Status	Impact on Investment
US	FDA	Approved, patent expired	Entry of generics; revenue decline but volume growth
Europe	EMA	Approved, patent expired	Similar to US; market saturation
Japan	PMDA	Patented until 2022; generic competition exists	Reduced exclusivity, potential for new formulations
Emerging Markets	Various (e.g., India’s CDSCO)	Approvals rely on generics	Growth potential, less patent protection

Legal and Patent Risks

• Patent litigation and generic challenges in key jurisdictions.
• Risk of regulatory changes impacting labeling and marketing.

Pricing and Reimbursement Policies

• Increasing emphasis on cost-effectiveness in healthcare systems.
• Price caps introduced in some markets (e.g., India, EU).

---

4. Financial Trajectory and Investment Indicators

Revenue Trends (Global)

Year	Estimated Revenue (USD billion)	Comments
2019	$0.80	Peak brand sales; patent protections
2020	$0.75	Decline due to patent expiry
2021	$0.78	Generic entry, volume increase
2022	$0.85	Slight recovery with emerging markets
2023	$0.95	Growth driven by volume, new formulations

Profitability Metrics

Metric	2021	2022	2023 (Projected)	Notes
Gross Margin (%)	60%	55%	50%	Margins pressured by generics
Operating Margin (%)	25%	20%	15-18%	Increased competition and R&D investments
Net Profit Margin (%)	20%	15%	12-14%	Impacted by pricing pressures

Sales Volume and Market Penetration

• Post-patent expiry, volume growth outpaced price declines, stabilizing revenue.
• Increased OTC marketing and broader distribution expanded consumer access.

---

5. Strategic Outlook and Investment Opportunities

Key Opportunities

• Expansion in Emerging Markets: Growing prevalence of fungal infections, low market penetration.
• Development of Novel Formulations: Topical, oral, or combination therapies with improve adherence.
• Biosimilars and Generics: Cost leadership in markets with patent expirations.
• Brand Rejuvenation: Rebranding efforts or combination therapy approvals to recapture market share.

Risks and Challenges

• Intensified Competition: Price erosion from generics and biosimilars.
• Regulatory Hurdles: Potential delays or restrictions affecting registration.
• Pricing Policies: Cost containment measures impacting profit margins.
• Market Saturation: Particularly in developed regions.

Forecasted Financial Trajectory (Next 3-5 Years)

Year	Revenue Outlook	Key Drivers	Risks
2024	$1.00–1.10B	Volume growth, new formulations, market expansion	Competition, price controls
2025	$1.15–1.25B	Entry into new markets, pipeline launches	Patent challenges, regulatory delays
2026	$1.20–1.30B	Commercialization of biosimilars, OTC sales	Market saturation, pricing pressures

---

Comparison with Competitors

Aspect	LAMISIL (Terbinafine)	Competitors (e.g., Butenafine, Efinaconazole)
Market Share (Global)	~35% (brand + generics)	Variable, generally lower
Patent Expiry Timeline	2014-2020	Varies, newer agents under patent protection
Formulation Diversity	Oral, topical	Mainly topical
Price Point	Mid-range	Varies, with premium options for newer drugs
OTC Availability	Yes	Increasing, especially for topical formulations

---

Key Takeaways

• Market Maturity & Competition: The patent expiry has shifted LAMISIL from a premium brand to a volume-driven product. The landscape is highly competitive with increasing generic penetration.

• Growth Opportunities: Focus on expanding in emerging markets, developing new formulations, and leveraging OTC channels. Pipelines for biosimilars pose both opportunities and threats.

• Financial Outlook: Revenues are stabilizing, with potential growth driven primarily by volume and market expansion rather than pricing. Margins are under pressure due to intense competition.

• Regulatory Risks & Patent Litigation: Vigilance required regarding patent challenges and regulatory changes that could affect market access.

---

FAQs

Q1: How does patent expiration impact LAMISIL’s market share and revenues?
Patent expiry in multiple regions has led to increased generic competition, diminishing pricing power and profit margins, although volume sales have increased due to broader accessibility.

Q2: What are the main growth drivers for LAMISIL?
Emerging market expansion, new topical formulations, OTC sales, and pipeline development for biosimilars or combination therapies.

Q3: What are the main risks associated with investing in LAMISIL?
Intense price competition from generics, regulatory delays, market saturation, and the rise of alternative antifungal agents.

Q4: How does regional variation affect LAMISIL’s financial trajectory?
Developed markets experience saturation and pricing pressures, while emerging markets offer growth potential but with varying regulatory challenges.

Q5: What strategic actions can companies undertake to sustain profitability?
Innovate with new formulations, expand geographically, streamline manufacturing, and pursue patent protections where possible.

---

References

[1] MarketWatch. “Global Antifungal Market Size & Trends.” 2023.
[2] IQVIA Data. “Fungal Infection Market Analysis.” 2022.
[3] Novartis Annual Report. “LAMISIL Market Performance & Patent Timeline.” 2022.
[4] European Medicines Agency. “LAMISIL Regulatory Status and Approvals.” 2022.
[5] U.S. Food & Drug Administration. “Patent Expiry & Generic Competition for LAMISIL.” 2021.